These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6783143)

  • 21. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
    Góra-Tybor J; Robak T; Warzocha K; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
    Naujokaitis SA
    Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Strategy of antileukemic agents; the relationship between in vitro cell-killing kinetics and in vivo chemotherapeutic effects (author's transl)].
    Shimoyama M
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):695-706. PubMed ID: 4480564
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Planning combined therapy--the interaction of experimental and clinical studies.
    Carter SK
    Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination chemotherapy: considerations for design and analysis.
    Lloyd HH
    Cancer Chemother Rep 2; 1974 Mar; 4(1):157-65. PubMed ID: 4826495
    [No Abstract]   [Full Text] [Related]  

  • 28. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Zheng LM; Li Z; Liu L; Song BL; King I
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A regression survival model for testing the proportional hazards hypothesis.
    Quantin C; Moreau T; Asselain B; Maccario J; Lellouch J
    Biometrics; 1996 Sep; 52(3):874-85. PubMed ID: 8924576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.
    Moran RE; Straus MJ
    Cancer Treat Rep; 1980 Jan; 64(1):81-6. PubMed ID: 7379059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
    Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
    Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
    Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
    Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
    Anderson KC; Humphrey RL; Sensenbrenner LL
    Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A relative survival regression model using B-spline functions to model non-proportional hazards.
    Giorgi R; Abrahamowicz M; Quantin C; Bolard P; Esteve J; Gouvernet J; Faivre J
    Stat Med; 2003 Sep; 22(17):2767-84. PubMed ID: 12939785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.
    Grossie VB; Rosenblum MG; Loo TL
    Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].
    Kudriavtsev IA; Paramonova TD; Golenko OD; Miasishcheva NV
    Probl Gematol Pereliv Krovi; 1982 Jul; 27(7):27-31. PubMed ID: 7122454
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduced-rank hazard regression for modelling non-proportional hazards.
    Perperoglou A; le Cessie S; van Houwelingen HC
    Stat Med; 2006 Aug; 25(16):2831-45. PubMed ID: 16158396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic evaluation of the effect of hydroxyurea on viability of replicating cultured leukemia L1210 cells.
    Wilkoff LJ; Lloyd HH; Dulmadge EA; Dixon GJ
    J Natl Cancer Inst; 1970 Jan; 44(1):201-9. PubMed ID: 11515031
    [No Abstract]   [Full Text] [Related]  

  • 40. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.